Plain-English translation of NCT06169540 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at Massachusetts General Hospital are studying tiny particles in saliva called extracellular vesicles to see if they could help doctors better understand and monitor heart failure. The study compares saliva and blood samples from three groups: people hospitalized with acute heart failure, people with stable chronic heart failure, and healthy volunteers. The goal is to learn whether saliva could be a simple, non-invasive way to track how well a patient's heart condition is improving.
Currently, doctors rely on blood tests and imaging to diagnose and monitor heart failure, but these methods can be inconvenient and expensive. This research explores whether saliva—something easy to collect—contains biological clues that could help doctors detect heart failure earlier or better track a patient's response to treatment.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will provide one saliva sample and one blood sample during a single visit. If you are in the acute heart failure group, samples will be collected when you arrive at the hospital and again before discharge. The entire process takes about 15–30 minutes, and there is minimal discomfort involved—similar to a routine blood draw and a simple saliva collection.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States
Sponsor
Massachusetts General Hospital
Enrollment target
~90 participants
Started
April 2023
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Saumya Das, MD, PhD
Massachusetts General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.